Corporate ActionAug 7, 2026, 05:24 PM
BioStem Technologies Registers 3.57M Shares for Resale
AI Summary
BioStem Technologies, Inc. filed an S-1/A registration statement for the resale of up to 3,571,429 shares of common stock by a selling stockholder. These shares include those issued from a May 2026 private placement and potential anti-dilution adjustments. The company will not receive any proceeds from this resale. The filing also details the January 2026 acquisition of BioTissue's surgical and wound care business and highlights the company's history of net losses and going concern doubts.
Key Highlights
- Registers up to 3,571,429 common shares for resale by a selling stockholder.
- Shares include 746,269 from May 2026 private placement and 2,825,160 from anti-dilution.
- Company will not receive any proceeds from the selling stockholder's resale of shares.
- Acquired BioTissue's surgical and wound care business on January 21, 2026.
- May 2026 private placement raised approximately $2.5 million for the company.
- Reported pro forma net loss of $8.04 million for Q1 2026.
- Identified conditions raising substantial doubt about ability to continue as a going concern.
- Incurred a net loss of $6.6 million in FY 2025, with $21.2 million accumulated deficit.
Price Impact